Skip to content

Study · Randomized controlled trial · 2020

10 results

Liraglutide or insulin glargine treatments improves hepatic fat in obese patients with type 2 diabetes and nonalcoholic fatty liver disease in twenty-six weeks: A randomized placebo-controlled trial.

Guo W, Tian W, Lin L, Xu X

Diabetes research and clinical practice6 Oct 2020Cited by 103 (Europe PMC)

PMID33035599 (opens in a new tab)DOI10.1016/j.diabres.2020.108487 (opens in a new tab)PepBankPUB-33035599
Publisher pagePubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on background metformin, liraglutide significantly decreased intrahepatic lipid content from baseline to week 26 compared with placebo.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered liver fat more than placebo over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseIntrahepatic content of lipid (IHCL) change
    Study

    n: not reported in source

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Measurements

    IHCL
    26.4%
    liraglutide baseline
    IHCL
    20.6%
    liraglutide week 26

    Source sentences

    Summary
    After 26 weeks of treatment, compared to the placebo group, in the liraglutide and insulin glargine groups, IHCL significantly decreased from baseline to week 26 (liraglutide 26.4% ± 3.2% to 20.6% ± 3.9%, P  0.05).
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, subcutaneous adipose tissue decreased significantly in the liraglutide group.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide reduced fat under the skin over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseSubcutaneous adipose tissue (SAT) change
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    SAT and VAT decreased significantly in the liraglutide group and in the insulin glargine group (P < 0.05).
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, visceral adipose tissue decreased significantly in the liraglutide group.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide reduced belly (visceral) fat over 26 weeks.

    Peptide
    Liraglutide
    Outcome
    DecreaseVisceral adipose tissue (VAT) change
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Primary
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    SAT and VAT decreased significantly in the liraglutide group and in the insulin glargine group (P < 0.05).
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, AST decreased significantly from baseline in the liraglutide group.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered the liver enzyme AST.

    Peptide
    Liraglutide
    Outcome
    DecreaseAST change
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, AST, ALT, and HOMA-IR decreased significantly from baseline.
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, ALT decreased significantly from baseline in the liraglutide group.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered the liver enzyme ALT.

    Peptide
    Liraglutide
    Outcome
    DecreaseALT change
    Study

    n: not reported in source

    Comparator
    Baseline
    Analysis
    Secondary
    Outcome group
    Liver fat and liver function · Liver
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, AST, ALT, and HOMA-IR decreased significantly from baseline.
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD, the fall in subcutaneous adipose tissue was greater with liraglutide than with insulin glargine (P < 0.05).

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide cut fat under the skin more than insulin glargine.

    Peptide
    Liraglutide
    Outcome
    DecreaseChange in SAT, liraglutide versus insulin glargine
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔSAT and ΔVAT were greater with liraglutide than insulin glargine, they were significantly different between the two groups (ΔSAT, -36 vs. - 24.5, P  0.05).
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD, the fall in visceral adipose tissue was numerically larger with liraglutide than with insulin glargine, but P > 0.05.

    In plain wordsIn adults with type 2 diabetes and fatty liver, belly fat fell more with liraglutide than insulin glargine, but not significantly.

    Peptide
    Liraglutide
    Outcome
    No significant changeChange in VAT, liraglutide versus insulin glargine
    Study

    n: not reported in source

    Comparator
    Insulin glargine
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    ΔSAT and ΔVAT were greater with liraglutide than insulin glargine, they were significantly different between the two groups (ΔSAT, -36 vs. - 24.5, P  0.05).
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, HOMA-IR decreased significantly from baseline in the liraglutide group.

    In plain wordsIn adults with type 2 diabetes and fatty liver, liraglutide lowered HOMA-IR, a measure of insulin resistance.

    Peptide
    Liraglutide
    Outcome
    DecreaseHOMA-IR change
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    In the liraglutide group, AST, ALT, and HOMA-IR decreased significantly from baseline.
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In adults with type 2 diabetes and NAFLD on metformin, glucose lowering did not differ significantly among the liraglutide, insulin glargine and placebo groups.

    In plain wordsIn adults with type 2 diabetes and fatty liver, blood sugar lowering was not significantly different among liraglutide, insulin glargine and placebo.

    Peptide
    Liraglutide
    Outcome
    No significant changeGlucose-lowering among groups
    Study

    n: not reported in source

    Comparator
    Placebo and insulin glargine
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    There was no significant difference in glucose-lowering among the three groups.
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.
  10. 10HumanRandomized controlled trialSafety outcome

    In adults with type 2 diabetes and NAFLD, the abstract states that safety in the three groups performed well.

    In plain wordsIn adults with type 2 diabetes and fatty liver, the study reports that safety was good in all three groups.

    Peptide
    Liraglutide
    Outcome
    Not applicableOverall safety
    Study

    n: not reported in source

    Comparator
    Placebo and insulin glargine
    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated · 26 weeksAs given in this study (human).

    Source sentences

    Summary
    During the treatment, the safety of the three groups performed well.
    2 context sentences
    Summary · context
    This is a 26-week, single-center, prospective, randomized placebo-controlled study.
    Summary · context
    A total of 96 patients with type 2 diabetes and NAFLD under inadequate glycemic control by metformin were randomized (1:1:1) to receive add-on insulin glargine, liraglutide, or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.